Company intelligence / Profile preview

Regenesis

Ownership: Private
Development stage: Commercial

Overview

Regenesis Biotech offers commercial services in genetic testing for disease predisposition and dental pulp stem cell banking. They highlight the utility of early detection of high-risk genes such as BRCA1/2 and promote the future therapeutic potential of stored dental pulp mesenchymal stem cells. The company emphasizes accessibility and affordability in advanced healthcare solutions.

Therapeutic areas: OtherOncologyHematology
Modalities: Genetic testing serviceStem cell therapyExosome-based therapy
Industry: Molecular Diagnostics

Drug pipeline

3 assets

PlumeStop

Commercial

Indications: PFAS contamination, Groundwater contamination

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Regenesis.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Regenesis.

Explore the full profile